Estrogen receptor-α methylation predicts melanoma progression

Takuji Mori, Steve R. Martinez, Steven J. O'Day, Donald L. Morton, Naoyuki Umetani, Minoru Kitago, Atsushi Tanemura, Sandy L. Nguyen, Andy N. Tran, He Jing Wang, Dave S B Hoon

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

The role of estrogen receptor α (ER-α) in melanoma is unknown. ER-α expression may be regulated in melanoma via hypermethylation of promoter CpG islands. We assessed ER-α hypermethylation in primary and metastatic melanomas and sera as a potential tumor progression marker. ER-α methylation status in tumor (n = 107) and sera (n = 109) from American Joint Committee on Cancer (AJCC) stage I to IV melanoma patients was examined by methylation-specific PCR. The clinical significance of serum methylated ER-α was assessed among AJCC stage IV melanoma patients receiving biochemotherapy with tamoxifen. Rates of ER-α methylation in AJCC stage I, II, and III primary melanomas were 36% (4 of 11), 26% (5 of 19), and 35% (8 of 23), respectively. Methylated ER-α was detected in 42% (8 of 19) of stage III and 86% (30 of 35) of stage IV metastatic melanomas. ER-α was methylated more frequently in metastatic than primary melanomas (P = 0.0003). Of 109 melanoma patients' sera in AJCC stage I, II, III, and IV, methylated ER-α was detected in 10% (2 of 20), 15% (3 of 20), 26% (5 of 19), and 32% (16 of 50), respectively. Serum methylated ER-α was detected more frequently in advanced than localized melanomas (P = 0.03) and was the only factor predicting progression-free [risk ratio (RR), 2.64; 95% confidence interval (95% CI), 1.36-5.13; P = 0.004] and overall survival (RR, 2.31; 95% CI, 1.41-5.58; P = 0.003) in biochemotherapy patients. Hypermethylated ER-α is a significant factor in melanoma progression. Serum methylated ER-α is an unfavorable prognostic factor.

Original languageEnglish (US)
Pages (from-to)6692-6698
Number of pages7
JournalCancer Research
Volume66
Issue number13
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Estrogen Receptors
Methylation
Melanoma
Serum
Neoplasms
Odds Ratio
Confidence Intervals
CpG Islands
Tamoxifen
Tumor Biomarkers
Polymerase Chain Reaction
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mori, T., Martinez, S. R., O'Day, S. J., Morton, D. L., Umetani, N., Kitago, M., ... Hoon, D. S. B. (2006). Estrogen receptor-α methylation predicts melanoma progression. Cancer Research, 66(13), 6692-6698. https://doi.org/10.1158/0008-5472.CAN-06-0801

Estrogen receptor-α methylation predicts melanoma progression. / Mori, Takuji; Martinez, Steve R.; O'Day, Steven J.; Morton, Donald L.; Umetani, Naoyuki; Kitago, Minoru; Tanemura, Atsushi; Nguyen, Sandy L.; Tran, Andy N.; Wang, He Jing; Hoon, Dave S B.

In: Cancer Research, Vol. 66, No. 13, 01.07.2006, p. 6692-6698.

Research output: Contribution to journalArticle

Mori, T, Martinez, SR, O'Day, SJ, Morton, DL, Umetani, N, Kitago, M, Tanemura, A, Nguyen, SL, Tran, AN, Wang, HJ & Hoon, DSB 2006, 'Estrogen receptor-α methylation predicts melanoma progression', Cancer Research, vol. 66, no. 13, pp. 6692-6698. https://doi.org/10.1158/0008-5472.CAN-06-0801
Mori T, Martinez SR, O'Day SJ, Morton DL, Umetani N, Kitago M et al. Estrogen receptor-α methylation predicts melanoma progression. Cancer Research. 2006 Jul 1;66(13):6692-6698. https://doi.org/10.1158/0008-5472.CAN-06-0801
Mori, Takuji ; Martinez, Steve R. ; O'Day, Steven J. ; Morton, Donald L. ; Umetani, Naoyuki ; Kitago, Minoru ; Tanemura, Atsushi ; Nguyen, Sandy L. ; Tran, Andy N. ; Wang, He Jing ; Hoon, Dave S B. / Estrogen receptor-α methylation predicts melanoma progression. In: Cancer Research. 2006 ; Vol. 66, No. 13. pp. 6692-6698.
@article{c27d291303d34627949e5e0496a3ef6a,
title = "Estrogen receptor-α methylation predicts melanoma progression",
abstract = "The role of estrogen receptor α (ER-α) in melanoma is unknown. ER-α expression may be regulated in melanoma via hypermethylation of promoter CpG islands. We assessed ER-α hypermethylation in primary and metastatic melanomas and sera as a potential tumor progression marker. ER-α methylation status in tumor (n = 107) and sera (n = 109) from American Joint Committee on Cancer (AJCC) stage I to IV melanoma patients was examined by methylation-specific PCR. The clinical significance of serum methylated ER-α was assessed among AJCC stage IV melanoma patients receiving biochemotherapy with tamoxifen. Rates of ER-α methylation in AJCC stage I, II, and III primary melanomas were 36{\%} (4 of 11), 26{\%} (5 of 19), and 35{\%} (8 of 23), respectively. Methylated ER-α was detected in 42{\%} (8 of 19) of stage III and 86{\%} (30 of 35) of stage IV metastatic melanomas. ER-α was methylated more frequently in metastatic than primary melanomas (P = 0.0003). Of 109 melanoma patients' sera in AJCC stage I, II, III, and IV, methylated ER-α was detected in 10{\%} (2 of 20), 15{\%} (3 of 20), 26{\%} (5 of 19), and 32{\%} (16 of 50), respectively. Serum methylated ER-α was detected more frequently in advanced than localized melanomas (P = 0.03) and was the only factor predicting progression-free [risk ratio (RR), 2.64; 95{\%} confidence interval (95{\%} CI), 1.36-5.13; P = 0.004] and overall survival (RR, 2.31; 95{\%} CI, 1.41-5.58; P = 0.003) in biochemotherapy patients. Hypermethylated ER-α is a significant factor in melanoma progression. Serum methylated ER-α is an unfavorable prognostic factor.",
author = "Takuji Mori and Martinez, {Steve R.} and O'Day, {Steven J.} and Morton, {Donald L.} and Naoyuki Umetani and Minoru Kitago and Atsushi Tanemura and Nguyen, {Sandy L.} and Tran, {Andy N.} and Wang, {He Jing} and Hoon, {Dave S B}",
year = "2006",
month = "7",
day = "1",
doi = "10.1158/0008-5472.CAN-06-0801",
language = "English (US)",
volume = "66",
pages = "6692--6698",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Estrogen receptor-α methylation predicts melanoma progression

AU - Mori, Takuji

AU - Martinez, Steve R.

AU - O'Day, Steven J.

AU - Morton, Donald L.

AU - Umetani, Naoyuki

AU - Kitago, Minoru

AU - Tanemura, Atsushi

AU - Nguyen, Sandy L.

AU - Tran, Andy N.

AU - Wang, He Jing

AU - Hoon, Dave S B

PY - 2006/7/1

Y1 - 2006/7/1

N2 - The role of estrogen receptor α (ER-α) in melanoma is unknown. ER-α expression may be regulated in melanoma via hypermethylation of promoter CpG islands. We assessed ER-α hypermethylation in primary and metastatic melanomas and sera as a potential tumor progression marker. ER-α methylation status in tumor (n = 107) and sera (n = 109) from American Joint Committee on Cancer (AJCC) stage I to IV melanoma patients was examined by methylation-specific PCR. The clinical significance of serum methylated ER-α was assessed among AJCC stage IV melanoma patients receiving biochemotherapy with tamoxifen. Rates of ER-α methylation in AJCC stage I, II, and III primary melanomas were 36% (4 of 11), 26% (5 of 19), and 35% (8 of 23), respectively. Methylated ER-α was detected in 42% (8 of 19) of stage III and 86% (30 of 35) of stage IV metastatic melanomas. ER-α was methylated more frequently in metastatic than primary melanomas (P = 0.0003). Of 109 melanoma patients' sera in AJCC stage I, II, III, and IV, methylated ER-α was detected in 10% (2 of 20), 15% (3 of 20), 26% (5 of 19), and 32% (16 of 50), respectively. Serum methylated ER-α was detected more frequently in advanced than localized melanomas (P = 0.03) and was the only factor predicting progression-free [risk ratio (RR), 2.64; 95% confidence interval (95% CI), 1.36-5.13; P = 0.004] and overall survival (RR, 2.31; 95% CI, 1.41-5.58; P = 0.003) in biochemotherapy patients. Hypermethylated ER-α is a significant factor in melanoma progression. Serum methylated ER-α is an unfavorable prognostic factor.

AB - The role of estrogen receptor α (ER-α) in melanoma is unknown. ER-α expression may be regulated in melanoma via hypermethylation of promoter CpG islands. We assessed ER-α hypermethylation in primary and metastatic melanomas and sera as a potential tumor progression marker. ER-α methylation status in tumor (n = 107) and sera (n = 109) from American Joint Committee on Cancer (AJCC) stage I to IV melanoma patients was examined by methylation-specific PCR. The clinical significance of serum methylated ER-α was assessed among AJCC stage IV melanoma patients receiving biochemotherapy with tamoxifen. Rates of ER-α methylation in AJCC stage I, II, and III primary melanomas were 36% (4 of 11), 26% (5 of 19), and 35% (8 of 23), respectively. Methylated ER-α was detected in 42% (8 of 19) of stage III and 86% (30 of 35) of stage IV metastatic melanomas. ER-α was methylated more frequently in metastatic than primary melanomas (P = 0.0003). Of 109 melanoma patients' sera in AJCC stage I, II, III, and IV, methylated ER-α was detected in 10% (2 of 20), 15% (3 of 20), 26% (5 of 19), and 32% (16 of 50), respectively. Serum methylated ER-α was detected more frequently in advanced than localized melanomas (P = 0.03) and was the only factor predicting progression-free [risk ratio (RR), 2.64; 95% confidence interval (95% CI), 1.36-5.13; P = 0.004] and overall survival (RR, 2.31; 95% CI, 1.41-5.58; P = 0.003) in biochemotherapy patients. Hypermethylated ER-α is a significant factor in melanoma progression. Serum methylated ER-α is an unfavorable prognostic factor.

UR - http://www.scopus.com/inward/record.url?scp=33746159061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746159061&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-0801

DO - 10.1158/0008-5472.CAN-06-0801

M3 - Article

C2 - 16818643

AN - SCOPUS:33746159061

VL - 66

SP - 6692

EP - 6698

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -